CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will participate in two upcoming investor conferences:
- Canaccord Genuity Rare Disease and BioPharma 1x1 Day on Tuesday, February 7, 2017 in New York, NY
- 6th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 15, 2017 in New York, NY; presentation at 11:00 a.m. ET
Live audio webcast of the Leerink presentation be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. is a
leading microbiome therapeutics platform company developing a novel
class of biological drugs that are designed to treat disease by
restoring the function of a dysbiotic microbiome, where the natural
state of bacterial diversity and function is imbalanced. The Phase 2
study of Seres' program SER-109 has been completed in multiply recurrent C.
difficile infection. Seres' second clinical candidate, SER-287,
is being evaluated in a Phase 1b study in patients with mild-to-moderate
ulcerative colitis (UC). Seres is also developing SER-262, the first
ever synthetic microbiome therapeutic candidate, in a Phase 1b study in
patients with primary C. difficile infection. For more
information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
